In the Pipeline

A GSK/Sirtris Wrap-Up

Nature Biotechnology weighs in on the GSK/Sirtris controversy. They have a lot of good information, and I’m not just saying that because someone there has clearly read over the comments that have showed up to my posts on the subject.

Read the full story

Posted in In the PipelineComments (0)

Hope Darn Well Springs Eternal

Well, it takes all kinds to make a market. And the collapse in Medivation’s shares after their disastrous Phase III results the other day seem to have brought out some hopeful buyers.

Read the full story

Posted in In the PipelineComments (0)

Bad News at Exelixis

I’m hearing from more than one source that Exelixis has laid off about 40% of their work force, which is somewhere around 250 people (the numbers I get don’t all agree). This seems to be across the board, all departments, and most everyone is being asked to leave today

Read the full story

Posted in In the PipelineComments (0)

Not Gonna Make That One

A discussion at work the other day got me to thinking: what structures do you medicinal chemists out there just refuse to work on?

Read the full story

Posted in In the PipelineComments (0)

Merck/Schering-Plough People?

Kim Girard, a reporter from CBS Interactive is doing a story on how people are coping with the merger - if you’d like to speak with her, she’s at (de-spammified): kim.berg30-at-gmail.com.

Read the full story

Posted in In the PipelineComments (0)

Friday Book Recommendation

Here’s another outside the field - in fact, it’s outside of a lot of people’s fields. Where Is Everybody?

Read the full story

Posted in In the PipelineComments (0)

Twelve and One Half Per Cent

I will note here, with no additional comment whatsoever, that Jeff Kindler, Pfizer’s CEO, has just been granted a raise in his base salary of 12.5%. Details at Pharmalot .

Read the full story

Posted in In the PipelineComments (0)

Your Own Personal Bacteria

There’s a report in Nature on the bacteria found in the human gut that’s getting a lot of press today (especially for a paper about, well, bacteria in the human gut). A team at the Beijing Genomics Institute, with many collaborators, has done a large shotgun sequencing effort on gut flora and identified perhaps one thousand different species. I can well believe it

Read the full story

Posted in In the PipelineComments (0)

Dimebon, Grasping at Straws

Robert Langreth, an editor at Forbes, points to a possible way that Dimebon could get approval for Alzheimer’s: for its behavioral effects, not anything to do with amyloid or memory. I’m not buying it, I have to say.

Read the full story

Posted in In the PipelineComments (0)

Mental Health Break: The Alkali Metals Show Their Personalities

Some blogs run pictures of cats to give the readers a break from the ordinary.

Read the full story

Posted in In the PipelineComments (0)


Ask Our Experts

Dawn Obermoeller

Dawn Obermoeller
Social Media

Jonathan Richman

Jonathan Richman
Non-Personal Promotion

Optimize RX

Optimize RX
Internet Marketing & Analytics

Share Your Knowledge

We are always seeking seasoned pharmaceutical marketing professonals as contributors. If you have a strong background in pharmacetical marketing, and are interested in sharing your skills and knowledge with our community, or syndicating your existing blog posts, please click here.

Site Sponsored by

Interested in sponsoring on this site? Please click here.

Vendor Ratings

If you have had a positive experience with a pharmaceutical vendor, and would like to recommend that they be added to our vendor database, please click here.